Ureido substituted pyrrolidines

US6548533B2 · kind B2 · utility

Assignee

• AVENTIS PHARMA LIMITED · GB

Inventors

• Jean-Dominique Bourzat · Saint-Mandé, FR
• Alain Commercon · Vitry-sur-Seine, FR
• Bruno Filoche · Créteil, FR

Key dates

• Filing date: Nov 2, 2001
• Grant date: Apr 15, 2003
• Expiry date: Nov 2, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention is directed to physiologically active compounds of formula (I): wherein one of A1, A2 and A3 represents NR2 and the others represent C(R3)(R4); R1 represents R5Z1—Het— or R6N(R7)—C(═O)—NH—Ar2—; Ar1 represents aryldiyl or heteroaryldiyl; L1 represents a —R12-R13— linkage (where R12 is a direct bond or an alkylene chain, an alkenylene chain or an alkynylene chain and R13 is a direct bond, cycloalkylene, heterocycloalkylene, aryldiyl, heteroaryldiyl, —C(═Z3)—NR11—, —NR11—C(═Z3)—, —Z3—, —C(═O)—, —C(═NOR11)—, —NR11—, —NR11—C(═Z3)—NR11—, —SO2—NR11—, —NR —SO2—, —O—C(═O)—, —C(═O)—O—, —NR11—C(═O)—O— or —O—C(═O)—NR11—); and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs.Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronecti…